BioSpace News Archive

CMO Stephen Brannan to present Phase 1 results of a multi-dose safety study aimed at optimizing combination of Xanomeline and Trospium Chloride

Jazz Pharmaceuticals plc today announced that its Board of Directors has authorized a $400 million increase in the company’s share repurchase program, which the company intends to use over time based on market conditions and other factors.

HCP, Inc. announced today that it has commenced a public offering of an aggregate of 14,000,000 shares of its common stock, consisting of 2,000,000 shares offered directly by the Company and 12,000,000 shares offered on a forward basis in connection with the forward sale agreement described below.

Mirati Therapeutics, Inc. today announced the appointment of Maya Martinez-Davis to the Company’s Board of Directors, effective immediately.

Champions Oncology, Inc. today announced it will report its financial and operational results for the second quarter ended October 31, 2018, on Monday, December 17, 2018.

Merck today announced that Adam H. Schechter, president of Global Human Health (GHH), is stepping down from his current position as of Dec. 31, 2018, and will be shifting to an advisory capacity to the CEO. The company is taking the opportunity to reshape its commercial organization and is creating two new Executive Committee roles.

Blue Latitude Health (BLH), a creative consultancy combining the commercial focus of a consultancy with the creative vision of an agency, today announces it is joining the Fishawack Group of Companies (Fishawack), one of the world’s foremost independent medical communications and medical marketing organisations.

Rafael Holdings, Inc. reported revenue of $1.1 million and a loss per share of $0.04 for the first quarter of its 2019 fiscal year, the three months ended October 31, 2018.

Advancing medical device safety remains a top priority of the U.S. Food and Drug Administration. This means we are committed to communicating when new, relevant information becomes available about device safety risks, to ensure doctors and patients are better informed about device benefits and risks.

Astellas Pharma Inc. today announced that XOSPATA® (generic name: gilteritinib) is now available for prescription in the United States for the treatment of adult patients who have relapsed or refractory (resistant to treatment) Acute Myeloid Leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.1